ATE353104T1 - Pseudotypierung von hiv vektoren mit mokola virenhüllen - Google Patents

Pseudotypierung von hiv vektoren mit mokola virenhüllen

Info

Publication number
ATE353104T1
ATE353104T1 AT02740846T AT02740846T ATE353104T1 AT E353104 T1 ATE353104 T1 AT E353104T1 AT 02740846 T AT02740846 T AT 02740846T AT 02740846 T AT02740846 T AT 02740846T AT E353104 T1 ATE353104 T1 AT E353104T1
Authority
AT
Austria
Prior art keywords
pseudotyping
enclosures
mokola virus
hiv vectors
virus
Prior art date
Application number
AT02740846T
Other languages
English (en)
Inventor
Chamsy Sarkis
Yi He
Che Serguera
Noelle Dufour
Jacques Mallet
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE353104T1 publication Critical patent/ATE353104T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Peptides Or Proteins (AREA)
AT02740846T 2001-06-01 2002-05-31 Pseudotypierung von hiv vektoren mit mokola virenhüllen ATE353104T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0107239A FR2825372B1 (fr) 2001-06-01 2001-06-01 Pseudotypage des vecteurs vih-1 par des enveloppes de rhabdovirus

Publications (1)

Publication Number Publication Date
ATE353104T1 true ATE353104T1 (de) 2007-02-15

Family

ID=8863893

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02740846T ATE353104T1 (de) 2001-06-01 2002-05-31 Pseudotypierung von hiv vektoren mit mokola virenhüllen

Country Status (7)

Country Link
US (1) US7749973B2 (de)
EP (1) EP1392838B1 (de)
AT (1) ATE353104T1 (de)
CA (1) CA2448947C (de)
DE (1) DE60217958T2 (de)
FR (1) FR2825372B1 (de)
WO (1) WO2002097104A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2872170B1 (fr) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
WO2009016433A2 (en) * 2006-09-15 2009-02-05 Ottawa Health Research Institute Oncolytic rhabdovirus
US7786091B2 (en) * 2008-01-28 2010-08-31 The Regents Of The University Of California Compositions and methods for ameliorating myosin VIIa defects
CN101532031B (zh) * 2009-03-03 2011-04-20 上海吉盛制药技术有限公司 非整合慢病毒载体系统及其制备与应用
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
EP3119406B1 (de) * 2014-03-18 2021-01-20 Carmel-Haifa University Economic Corporation Ltd Verfahren zur verbesserung der kognitiven funktion durch modulation von chinon-reduktase 2
EP3501511A1 (de) * 2017-12-22 2019-06-26 Fundación Centro Nacional De Investigaciones Oncológicas Carlos III Mittel zur prävention und behandlung von gehirnmetastasen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE404683T1 (de) * 1992-09-25 2008-08-15 Aventis Pharma Sa Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
DE69941049D1 (de) * 1998-05-22 2009-08-13 Oxford Biomedica Ltd Retrovirales verabreichungssystem

Also Published As

Publication number Publication date
US7749973B2 (en) 2010-07-06
US20040120929A1 (en) 2004-06-24
FR2825372B1 (fr) 2004-06-18
DE60217958T2 (de) 2007-11-08
DE60217958D1 (de) 2007-03-22
CA2448947C (fr) 2011-07-12
EP1392838B1 (de) 2007-01-31
CA2448947A1 (fr) 2002-12-05
FR2825372A1 (fr) 2002-12-06
WO2002097104A1 (fr) 2002-12-05
EP1392838A1 (de) 2004-03-03

Similar Documents

Publication Publication Date Title
ATE370229T1 (de) Ein verstärkter, durch viren vermittelter dna- transfer
Tober et al. VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications
DE69435316D1 (de) Verfahren zur herstellung von hohen virustitern und die hocheffiziente transduktion von säugerzellen durch retroviren
FI970983A0 (fi) Molekyylien siirto solujen sytoplasmaan
DE69532369D1 (de) Rekombinantes infektiöses nicht-in-Segmente-geteiltes, negativ-Strange-RNS-Virus
DK1792997T3 (da) Lentiviral triplex DNA og vektorer og rekombinante celler indeholdende lentiviralt triplex DNA
ES2004133A6 (es) Procedimiento para la preparacion de una nueva proteina.
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
ATE310089T1 (de) Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen
ATE325533T1 (de) Verfahren zum verbesserten virusvermittelten dns- transfer unter verwendung von molekülen mit virus-und zellbindenden domänen
DE60238472D1 (de) Abschwächung der immunogenizität von fusionsproteinen
DK1372710T3 (da) MVA der udtrykker modificeret HIV-kappe-, Gag- og Pol-gener
ATE353104T1 (de) Pseudotypierung von hiv vektoren mit mokola virenhüllen
DK79985A (da) Kloning af dna for protozoelle antigener og dets anvendelse
MXPA02007478A (es) Vacuna contra el virus de inmunodeficiencia humana.
NO20020571L (no) Peptider som blokkerer infeksjonsevnen, og fremgangsmåter for anvendelse av disse
ATE135743T1 (de) Monoklonale menschliche antikörper gegen hiv-i
DK0981601T3 (da) Fremgangsmåder til dyrkning af celler og opformering af vira
DE69434173D1 (de) Herstellung von trehalose in pflanzen
ATE427119T1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
DE60042702D1 (de) Molekulare klone mit mutierten hiv gag/pol, siv gag und siv env gene
WO2003093431A3 (en) Ablated slam-dependent entry
EP1390388A4 (de) Antisense-modulation der expression des interferon-gamma-rezeptors 1
WO2006109174A3 (en) Hiv vaccine comprising a glycoprotein 120 signal sequence with no more than one positively charged amino acid
NZ507942A (en) Viral chimeras comprised of CAEV and HIV-1 genetic elements

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties